Search

Your search keyword '"Sheng F"' showing total 919 results

Search Constraints

Start Over You searched for: Author "Sheng F" Remove constraint Author: "Sheng F"
919 results on '"Sheng F"'

Search Results

1. Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer

3. BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon

4. Analysis of potential genes associated with primary cilia in bladder cancer

6. Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia

7. Analysis Of Hotspots In The Field Of Domestic Knowledge Discovery Based On Co-Word Analysis Method

10. Differentiation-dependent expression and localization of the class B type I scavenger receptor in intestine

11. Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study

12. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML

13. MEN1 mutations mediate clinical resistance to menin inhibition

14. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

18. Supplementary Figure S1 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms

19. Supplementary Table S2 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms

20. Data from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms

22. Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms

23. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia

24. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

30. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia

31. MEN1 mutations mediate clinical resistance to menin inhibition

34. S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6A

37. A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up

38. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia

39. Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

40. Metabolic and magnetic resonance imaging: complementary modalities for the preoperative assessment of lateral pelvic lymph nodes in rectal cancer

41. ENRICHMENT EFFECT OF PHYTOHORMONES ON ARSENIC UPTAKE AND TOLERANCE MECHANISM OF LANDOLTIA PUNCTATA.

43. Abstract 3457: Characterization of acquired resistance mutations to menin inhibitors

44. Data from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

45. Supplementary Table 1 from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

46. Supplementary Table 2 from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

47. Supplementary Data from Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

Catalog

Books, media, physical & digital resources